Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

June 19, 2020 — Researchers have developed LIH383, a novel molecule that binds to and blocks a previously unknown opioid receptor in the brain, thereby modulating the levels of opioid peptides ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Glucagon-like peptide receptor agonists (GLP-1RAs ... Now, these drugs are being investigated for a new and unexpected application: opioid use disorder (OUD). Last month, Eli Lilly CEO Dave ...

About Cebranopadol (TRN-228) Cebranopadol is a first-in-class investigational therapy that targets two key receptors, the nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP ...

Cebranopadol – a dual-NMR agonist working on nociceptin/orphanin FQ peptide (NOP) and mu-opioid peptide (MOP) receptors – is a potential first-in-class alternative to opioid analgesics ...

Topline results were announced from a phase 3 trial evaluating cebranopadol for the treatment of moderate to severe acute pain in patients following ...

Purpose. Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP ...